GI Cancer Program, Surgical Oncology at UT Southwestern Medical Center, Dallas
General Surgery
Dr. Roderich Schwarz, MD
|
|
Give Review
Doctor Roderich Schwarz, MD works in the field of General Surgery. He studied medicine at Hannover Medical School. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Fellow (FACS)". Roderich Schwarz is also published. He has 65 publications published. The lastest publication: "N-terminus of pro-EMAP II regulates its binding with C-terminus, Arginyl-tRNA Synthetase, and Neurofilament light protein.' Roderich Schwarz accepts all Medicare patients.
Publications
- N-terminus of pro-EMAP II regulates its binding with C-terminus, Arginyl-tRNA Synthetase, and Neurofilament light protein.
- Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic Cancer.
- Liver resection for metastatic Disease after y90 radioembolization: a case series with long-term follow-up.
- Biliary obstruction and postoperative morbidity after pancreatoduodenectomy: what still obstructs clearance to clearance of obstruction.
- Enhancement of Nab-paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer.
- A Comparison of Five Competing Lymph Node Staging Schemes in a Cohort of Resectable Gastric Cancer Patients.
- The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric Cancer.
- Is timing to delivery of treatment a reliable measure of quality of care for patients with coloRectal adenocarcinoma?
- Laparoscopy-assisted resection of proximal gastric Cancer: is less than all more or less complete, or is all more, nonetheless?
- PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic Cancer.
- Superior antitumor activity of nanoparticle albumin-bound Paclitaxel in experimental gastric Cancer.
- Systemic cytotoxic and biological therapies of coloRectal liver metastases: expert consensus statement.
- Pancreatic Neuroendocrine Tumors: Signal Pathways and Targeted Therapies.
- Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic Cancer.
- The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic Cancer.
- Survival impact of malignant pancreatic Neuroendocrine and islet cell neoplasm phenotypes.
- Transplantation for hepatocellular Carcinoma as part of a balanced, multidisciplinary strategy.
- Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.
- Resection of type I gastric carcinoid: when and why?
- Challenges with demographic disparities in gastric Cancer care and survival: spectral rather than black and white.
- Enhancing cytotoxic agent activity in experimental pancreatic Cancer through EMAP II combination therapy.
- Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic Cancer.
- EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic Cancer.
- Antitumor effects of EMAP II against pancreatic Cancer through inhibition of fibronectin-dependent proliferation.
- Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal Cancer: a North Central Cancer Treatment Group (NCCTG)/ National...
- An antiendothelial combination therapy strategy to increase survival in experimental pancreatic Cancer.
- Pathologic response to preoperative therapy: does it mean what we think it means?
- Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling.
- Molecular mechanisms for individualized Cancer care.
- Trends in local therapy for hepatocellular Carcinoma and survival outcomes in the US population.
- Extended left-sided pancreatectomy with spleen preservation.
- Pancreatoduodenectomy with or without pyloric preservation: a clinical outcomes comparison.
- Clinical impact of lymphadenectomy extent in resectable esophageal Cancer.
- Androgen receptor blockade in experimental combination therapy of pancreatic Cancer.
- Factors influencing perioperative blood transfusions in patients with gastrointestinal Cancer.
- Estrogen receptor beta/alpha ratio predicts response of pancreatic Cancer cells to estrogens and phytoestrogens.
- Phase I trial of intraperitoneal gemcitabine in the treatment of advanced Malignancies primarily confined to the peritoneal cavity.
- Lymph node dissection impact on staging and survival of extrahepatic cholangioCarcinomas, based on U.S. population data.
- Clinical impact of lymphadenectomy extent in resectable gastric Cancer of advanced stage.
- Extent of lymph node retrieval and pancreatic Cancer survival: information from a large US population database.
- More on: what's in a name, of and around the pancreas?
- Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin.
- Paint-only is equivalent to scrub-and-paint in preoperative preparation of Abdominal surgery sites.
- Impact of total lymph node count on staging and survival after gastrectomy for gastric Cancer: data from a large US-population database.
- Extended lymph node dissection for gastric Cancer: who may benefit? Final results of the randomized Dutch gastric Cancer group trial.
- Image of the month--giant multicystic lymphangioma.
- Immunohistochemical staining in the diagnosis of pancreatoBiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
- Hypomagnesemia after major Abdominal operations in cancer patients: clinical implications.
- Defining palliation in patients undergoing gastrectomy for gastric Cancer.
- Gastric adenomyoma: definitely benign or defiantly premalignant?
- Pancreatic tumors in patients with Lung malignancies: a spectrum of clinicopathologic considerations.
- Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic Carcinoma cells inhibits their invasive phenotype1.
- In vivo therapy of local tumor progression by targeting Vascular endothelium with EMAP-II.
- Complications of malignancy: case 2. Infectious tissue pneumatosis as a result of colon Cancer perforation in a survivor of Hodgkin's disease.
- Quality of life in patients with coloRectal metastasis and intrahepatic chemotherapy.
- Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score Analysis.
- Extrahepatic Bile duct stricture and elevated CA 19-9: malignant or benign?
- Extended lymph node dissection in gastric Carcinoma: where do we stand after the Dutch and British randomized trials?
- Long-term survival after radical operations for Cancer treatment-induced sarcomas: how two survivors invite reflection on oncologic treatment concepts.
- Unusual presentations of uncommon tumors: case 2. Gastric carcinoid metastatic to the Liver.
- Recurrence patterns after radical gastrectomy for gastric Cancer: prognostic factors and implications for postoperative adjuvant therapy.
- Simple feeding jejunostomy technique for postoperative nutrition after major upper gastroIntestinal resections.
- Significant hypomagnesemia after celiotomy: implications of preoperative bowel cleansing with sodium phosphate purgative.
- Spleen-preserving splenic hilar lymphadenectomy at the time of gastrectomy for Cancer: technical feasibility and early results.
Procedures Preformed
- Cholecystoenterostomy
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Excision of Bile Duct Tumor
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- View All
Conditions Treated
- Abdominal Pain
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Atelectasis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACS)
Education
-
University of Pittsburgh Medical Center -
Hannover Medical School
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871679589 |
| Last Name Of The Provider | SCHWARZ |
| First Name Of The Provider | RODERICH |
| View All |
Similar Doctors
|
Dr. Laura L. Morris, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John C. Martens, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Denise C. Murphy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathaniel T. Dew, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Daniel A. Diener, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Leonard R. Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John D. Abad, MD
This Doctor is OpenDoctor Recommended.
|